Nanoelectroablation Control and Vaccination
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 62/086,025, filed Dec 1, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,724,155 | Nanoelectroablation Control and Vaccination In force · High confidence | Pulse Biosciences, Inc. | In force | High confidence | ||
| US 10,058,383 | Nanoelectroablation Control and Vaccination In force · High confidence | Pulse Biosciences, Inc. | In force | High confidence | ||
| US 10,307,207 | Nanoelectroablation Control and Vaccination In force · Low confidence | Pulse Biosciences, Inc. | In force | Low confidence | ||
| US 10,695,127 | Nanoelectroablation Control and Vaccination In force · High confidence | Pulse Biosciences, Inc. | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.